登录

Denovo Biopharma Raises ¥590M in Series C Funding Round

作者: Mailman 2020-06-29 14:11
索元生物
http://www.denovobiopharma.com
企业数据由 动脉橙 提供支持
生物新药研发商 | D轮 | 运营中
中国-浙江
2020-12-08
融资金额:近亿人民币
盈科资本
查看

According to VCBeat, on June 29, 2020, Denovo Biopharma, a leading precision medicine company, announced the completion of ¥590 million Series C financing, led by CICC Qide Innovative Biomedicine Fund, with additional support from existing shareholders including Jiuyo Capital, Share Capital, CITIC Securities and Sangel Capital, and new investors including Yingke PE, Guozhong Capital and Kaitou Hanrun Investment.


Denovo Biopharma is a privately held biotech company providing a novel biomarker solution to personalize drug development. Its platform can be broadly applied to biomarker discovery in many therapeutic areas, such as oncology, metabolic, cardiology, immunology and neurology. 


Up to now, Denovo Biopharma has global rights of six first-in-class drugs (DB102 to DB107) that have been developed in the clinical stage for cancers and psychiatric diseases. DB102 (enzastaurin) is an anti-tumor drug that Lilly conducted many clinical studies within a variety of tumor indications. Then Denovo Biopharma acquired global rights to enzastaurin from Lilly and has completed the identification of the biomarker, which is significantly correlated with the expected therapeutic effects on DLBCL and GBM patients, and has filed international patent applications. 


The clinical trials of DB102 in several countries for newly diagnosed GBM has also been approved by the FDA and China's NMPA and will be conducted this year.


>>>>

About Jiuyo Capital


Founded by more than 100 partners with financial and industrial background, Jiuyo Capital is an equity investment firm. The company has three main business segments: investment management, FA services, and financial consulting. 


Jiuyo Capital mainly invests in the field of AI technology, communication technology, new materials, advanced manufacturing, innovative drugs, and precision medicine.


>>>>
About Share Capital


Founded in Shenzhen in 2007, Share Capital is the earliest professional venture capital firm of limited partnership in China. Share Capital focuses on the early and mid-stage investment in health care and housing. So far, it has established 11 funds with AUM over 8 billion yuan.

相关赛道 生物制药
注:文中如果涉及企业数据,均由受访者向分析师提供并确认。
声明:动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。转载请联系tg@vcbeat.net。

Mailman

医疗行业观察者

分享
动脉橙
以上数据来自动脉橙产业智库

我们以独创的在线数据库方式,为健康产业人士提供全方位和实时的市场资讯、行业数据和分析师见解。现已覆盖数字健康、医疗器械、生物医药等近500+细分赛道,涉及公司名单、招投标、投融资信息、头部企业动态等各类数据并持续更新。

点击 【申请试用】了解动脉橙产业智库更多内容。
精彩内容推荐

2023创新药及供应链白皮书:解读近400起融资事件,百余条临床管线与BD并购

【首发】独家专访“岷山行动”杨寒朔,联合君联资本孵化 “臻愈生物”并完成种子轮融资

【首发】可瑞生物完成Pre-A+轮融资,加速推进TCR创新药布局

【首发】泛恩生物完成近亿元Pre-A轮融资,独家专访创始人周鹏辉教授

Mailman

共发表文章3245篇

最近内容
  • 知之甚少:调研885名投资人后,原来美国VC们这样做决策

    2023-03-20

  • 辉瑞想要收购Seagen只是开始,这才是2023年并购的两大趋势

    2023-03-05

  • 【融资】核药企业Ratio再融资2000万美元,和拜耳合作研究新前列腺癌放射性疗法

    2023-02-09

上一篇

启明创投投资企业甘李药业成功登陆A股主板,开盘迅速涨停

2020-06-29
下一篇

Huizhen Bang Bags over ¥10M in Series A Financing

2020-06-29